EN
Press Releases
-
BEIJING, China, July 12, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it
-
![The Lancet Inf. Dis. Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Year]()
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3
-
![SINOVAC’s EV71 vaccine Inlive® is approved for children aged from 6 to 71 months]()
BEIJING – June 12, 2021 – SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Inlive®, an innovative, inact
-
![World Health Organization Authorizes SINOVAC’s CoronaVac<sup>®</sup> for Emergency Use]()
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, in
-
![EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated]()
-
BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securit
-
-
-
2021/02/22
Sinovac Amends Shareholder Rights Plan
-
-
-
-
2021/01/31
Clarification Statement
-
2021/01/28
Statement
-
-
-
-
-
-
![A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strain]()
Project Title:A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin StrainProtocol Title:A clinical trial with an open-label phase to evaluate the safety of Sa
